The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 26, 2024
Filed:
Jan. 05, 2022
Applicant:
Trellis Bioscience, Llc, Redwood City, CA (US);
Inventors:
Lawrence M. Kauvar, San Francisco, CA (US);
Stefan Ryser, Menlo Park, CA (US);
Angeles Estelles, Belmont, CA (US);
Reyna J. Simon, Los Gatos, CA (US);
Lauren Opremcak Bakaletz, Columbus, OH (US);
Steven David Goodman, Columbus, OH (US);
Assignee:
Trellis Bioscience, LLC, Redwood City, CA (US);
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/12 (2006.01); A61K 35/12 (2015.01); A61K 39/00 (2006.01); A61K 39/40 (2006.01); A61K 45/06 (2006.01); A61K 49/00 (2006.01); C07K 14/31 (2006.01); C12N 15/86 (2006.01); C12Q 1/18 (2006.01); G01N 33/566 (2006.01); G01N 33/569 (2006.01);
U.S. Cl.
CPC ...
C07K 16/1271 (2013.01); A61K 39/40 (2013.01); A61K 45/06 (2013.01); A61K 49/00 (2013.01); C07K 14/31 (2013.01); C07K 16/1214 (2013.01); C07K 16/1228 (2013.01); C07K 16/1242 (2013.01); C07K 16/1275 (2013.01); C12Q 1/18 (2013.01); G01N 33/566 (2013.01); G01N 33/56911 (2013.01); A61K 35/12 (2013.01); A61K 39/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01); C12N 15/86 (2013.01); G01N 2333/195 (2013.01); G01N 2333/21 (2013.01); G01N 2333/245 (2013.01); G01N 2333/26 (2013.01); G01N 2333/285 (2013.01); G01N 2469/10 (2013.01);
Abstract
Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.